Dr. Lawrence Eichenfield Unpacks New Phase 3 Data on Roflumilast Cream 0.05% in AD in Kids Aged 2 to 5 March 12, 2024
Sanofi’s OX40-ligand Blocker Produces High Durable Response Rates in AD With Quarterly Dosing March 11, 2024